Should you buy Merit Medical Systems (MMSI)?
Updated
Merit Medical Systems combines a perfect four-quarter earnings beat streak averaging nearly 13% upside, a maximum Piotroski financial health score of 9 out of 9, and free-cash-flow conversion at 128% of net income — but a confirmed death cross with the 200-day moving average declining at roughly 4% per month represents a hard technical block that makes the setup best suited to patient holders rather than new buyers.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
The company has beaten consensus earnings estimates in all four most recent quarters by an average of nearly 13%, while free cash flow converts at 128% of net income — a combination of delivery reliability and cash quality that is rare and supports confidence in the reported earnings. Earnings | The beat streak should continue, with EPS beating consensus in at least 3 of the next 4 quarters and average surprise remaining above 8%. | →Stable |
| CounterA four-quarter beat streak with strong averages can set a high market expectation baseline, making any single miss disproportionately punitive; cash conversion above 100% may also reflect favorable working-capital timing rather than a structural outperformance that will persist. | ||
A confirmed death cross is in place, the 200-day moving average is declining at roughly 4% per month, and a hard technical block has been triggered — conditions that typically require resolution before new buyers can achieve reliable entry timing. Engine gate (failed) | The 200-day moving average should stop declining and price should reclaim that level within 12 months for the technical obstruction to resolve. | →Stable |
| CounterRSI stands at 58 and MACD is improving — early recovery signals consistent with the setup; the longer-term moving average may be lagging a genuine momentum inflection that is already underway in shorter-term data. | ||
A Piotroski financial strength score of 9 out of 9 — the highest possible reading — signals that the business clears every standard financial health criterion simultaneously, reducing the risk of distress or forced dilution at inopportune times. Quality breakdown | The Piotroski score should sustain above 7 for at least the next 4 quarters, confirming that financial health is structural rather than a point-in-time reading. | →Stable |
| CounterPiotroski scores reflect past financial statements and may not anticipate forward balance-sheet pressures from growth investment, potential acquisitions, or rising debt service if the company increases leverage. | ||
The company has beaten consensus earnings estimates in all four most recent quarters by an average of nearly 13%, while free cash flow converts at 128% of net income — a combination of delivery reliability and cash quality that is rare and supports confidence in the reported earnings.
→Stable- Expectation
- The beat streak should continue, with EPS beating consensus in at least 3 of the next 4 quarters and average surprise remaining above 8%.
CounterA four-quarter beat streak with strong averages can set a high market expectation baseline, making any single miss disproportionately punitive; cash conversion above 100% may also reflect favorable working-capital timing rather than a structural outperformance that will persist.
A confirmed death cross is in place, the 200-day moving average is declining at roughly 4% per month, and a hard technical block has been triggered — conditions that typically require resolution before new buyers can achieve reliable entry timing.
→Stable- Expectation
- The 200-day moving average should stop declining and price should reclaim that level within 12 months for the technical obstruction to resolve.
CounterRSI stands at 58 and MACD is improving — early recovery signals consistent with the setup; the longer-term moving average may be lagging a genuine momentum inflection that is already underway in shorter-term data.
A Piotroski financial strength score of 9 out of 9 — the highest possible reading — signals that the business clears every standard financial health criterion simultaneously, reducing the risk of distress or forced dilution at inopportune times.
→Stable- Expectation
- The Piotroski score should sustain above 7 for at least the next 4 quarters, confirming that financial health is structural rather than a point-in-time reading.
CounterPiotroski scores reflect past financial statements and may not anticipate forward balance-sheet pressures from growth investment, potential acquisitions, or rising debt service if the company increases leverage.
▸ Show 1 more pillar▾ Show fewer
A strong growth profile across both revenue and earnings, at a forward P/E of 15.2 times and a PEG of 1.42, suggests the current multiple is reasonable relative to the growth trajectory — and analyst consensus implies approximately 34% upside to the target price.
→Stable- Expectation
- Revenue growth should sustain above 5% year-over-year for the next 4 quarters, and forward earnings estimates should hold or rise, preserving the multiple-support argument.
CounterVolume distribution (falling OBV) indicates institutional selling into the current price level, which can suppress the multiple even when underlying fundamentals are sound — suggesting the market may not yet accept the growth premium embedded in analyst targets.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has beaten consensus earnings estimates in all four most recent quarters by an average of nearly 13%, while free cash flow converts at 128% of net income — a combination of delivery reliability and cash quality that is rare and supports confidence in the reported earnings.
Trip ifEPS surprise falls below 0% in 2 consecutive quarters, ending the perfect beat streak.
- P2A confirmed death cross is in place, the 200-day moving average is declining at roughly 4% per month, and a hard technical block has been triggered — conditions that typically require resolution before new buyers can achieve reliable entry timing.
Trip ifThe 200-day moving-average slope rises above 0% and price holds above the 200-day moving average for 4 consecutive weeks, confirming the downtrend has reversed.
- P3A Piotroski financial strength score of 9 out of 9 — the highest possible reading — signals that the business clears every standard financial health criterion simultaneously, reducing the risk of distress or forced dilution at inopportune times.
Trip ifPiotroski financial strength score falls below 7 for 2 consecutive reporting periods, indicating meaningful deterioration in balance-sheet health.
- P4A strong growth profile across both revenue and earnings, at a forward P/E of 15.2 times and a PEG of 1.42, suggests the current multiple is reasonable relative to the growth trajectory — and analyst consensus implies approximately 34% upside to the target price.
Trip ifRevenue growth falls below 5% year-over-year for 2 consecutive quarters, compressing the growth-to-multiple justification.
How the engine reached this verdict
TrendMatrix's engine output for Merit Medical Systems, Inc. (MMSI) is HOLD_IF_HOLDING with medium conviction, score 5.7/10 at $69.97. None of the engine's positive-conviction paths (C-quality, D-momentum) cleared their gates — the F-path HOLD reflects balanced signals rather than directional conviction.
On the bull side: Strong earnings beat streak (4/4); Strong growth profile. On the bear side: Below 200-MA, MA slope -4.2%/30d (confirmed downtrend). Active engine warnings: V9 Gate Failed: ASYMMETRY:0.7<1.5@spot.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $66.29 for existing positions. Asymmetric R:R is 1.89, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
HOLD flips toward BUY_WAIT if reward-to-risk at 0.7 vs threshold 1.5 clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates MMSI — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (4/4)
- ▸Strong growth profile
Bear case
- ▸Below 200-MA, MA slope -4.2%/30d (confirmed downtrend)